SCHEMBL821285

SCHEMBL821285

C=CCNCC(=C)C(=O)O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 1/20 0.45
HSD17B10 Q99714 1/20 0.45
KDM4E B2RXH2 6/20 0.40
TSHR P16473 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
MAPT P10636 1/20 0.35
ALDH1A1 P00352 2/20 0.35
KMT2A Q03164 2/20 0.33
HTT P42858 1/20 0.33
USP2 O75604 1/20 0.33
TET2 Q6N021 3/20 0.32
TET3 O43151 1/20 0.32
TET1 Q8NFU7 1/20 0.32
NPC1 O15118 1/20 0.32
RAB9A P51151 1/20 0.32
GAA P10253 1/20 0.32
GRIK1 P39086 1/20 0.31
GRIK2 Q13002 1/20 0.31
GRM1 Q13255 1/20 0.31
GRM2 Q14416 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17727677 0.80 TSHR (0.37) ALOX15HSD17B10KDM4ETSHRSMN1; SMN2
Oxalic Acid SCHEMBL28044433 0.79 MAPT (0.41) ALOX15HSD17B10KDM4ETSHRSMN1; SMN2
SCHEMBL5140971 0.78 TSHR (0.42) KDM4ETSHRSMN1; SMN2MAPTALDH1A1
SCHEMBL1489418 0.78 ALOX15 (0.42) ALOX15HSD17B10KDM4ETSHRSMN1; SMN2
SCHEMBL29438 0.78
SCHEMBL3946913 0.78 MAPT (0.44) ALOX15HSD17B10KDM4ETSHRSMN1; SMN2
SCHEMBL4945287 0.77 ALOX15 (0.41) ALOX15HSD17B10KDM4ETSHRSMN1; SMN2
Water SCHEMBL7160929 0.76
SCHEMBL10869584 0.76
SCHEMBL7184515 0.76

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 156 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4395730-A1 DISSOLVABLE SOLID STRUCTURE COMPRISING FIRST AND SECOND POLYMERIC STRUCTURANTS The Procter & Gamble Company (US) 2024-07-10 EP claimed
US-11666514-B2 Fibrous structures containing polymer matrix particles with perfume ingredients THE PROCTER & GAMBLE COMPANY (US) 2023-06-06 US claimed
WO-2023034763-A1 DISSOLVABLE SOLID STRUCTURE COMPRISING FIRST AND SECOND POLYMERIC STRUCTURANTS THE PROCTER & GAMBLE COMPANY (US) 2023-03-09 WO claimed
US-20230060806-A1 DISSOLVABLE SOLID STRUCTURE COMPRISING FIRST AND SECOND POLYMERIC STRUCTURANTS THE PROCTER & GAMBLE COMPANY 2023-03-02 US claimed
CN-114599773-A Fabric care compositions with improved microbial robustness and methods of use thereof 高露洁-棕榄公司 2022-06-07 CN claimed
US-20200093710-A1 FIBROUS STRUCTURES CONTAINING POLYMER MATRIX PARTICLES WITH PERFUME INGREDIENTS THE PROCTER & GAMBLE COMPANY 2020-03-26 US claimed
EP-0991368-B2 POLYMERIZABLE ISOLATION BARRIERS AND METHODS FOR FORMING AND USING SUCH BARRIERS ULTRADENT PRODUCTS INC (US) 2017-05-10 EP claimed
US-9192908-B2 Encapsulated solid hydrophilic particles ENCAPSYS, LLC (US) 2015-11-24 US claimed
US-8715544-B2 Hydrophilic liquid encapsulates APPVION, INC. (US) 2014-05-06 US claimed
US-20130245153-A1 ENCAPSULATED SOLID HYDROPHILIC PARTICLES WELD-ON ADHESIVES, INC. 2013-09-19 US claimed
EP-0991368-A4 POLYMERIZABLE ISOLATION BARRIERS AND METHODS FOR FORMING AND USING SUCH BARRIERS ULTRADENT PRODUCTS INC (US) 2005-05-04 EP claimed
US-RE38721-E1 Polymerizable isolation barriers with reduced polymerization strength and methods for forming and using such barriers ULTRADENT PRODUCTS, INC. (US) 2005-04-12 US claimed
US-RE38722-E1 Polymerizable isolation barriers containing reflective materials and methods for forming and using such barriers ULTRADENT PRODUCTS, INC. (US) 2005-04-12 US claimed
EP-0906902-B1 A method for the production of an alkylamino (meth)acrylate and apparatus therefor. NIPPON CATALYTIC CHEM IND (JP) 2002-08-28 EP claimed
US-6305936-B1 UNSATURATED MONOMER, CURING AGENT, WET TISSUE ADHERENCE ACCENTUATOR, REFLECTIVE MATERIAL AND ORGANIC POLYMERIZATION STRENGTH REDUCER; CONFINING DENTAL TREATMENT ULTRADENT PRODUCTS, INC. 2001-10-23 US claimed
US-6268528-B1 OXIDIZING DIALKYLNAPHTHALENE TO NAPHTHALENEDICARBOXYLIC ACID IN SOLVENT CONTAINING LOWER ALIPHATIC CARBOXYLIC ACID USING MOLECULAR OXYGEN-CONTAINING GAS IN PRESENCE OF A CATALYST COMPRISING COBALT COMPOUND, MANGANESE COMPOUND AND BROMINE MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 2001-07-31 US claimed
US-6086370-A Polymerizable isolation barriers containing reflective materials and methods for forming and using such barriers ULTRADENT PRODUCTS, INC. (US) 2000-07-11 US claimed
EP-0991368-A1 POLYMERIZABLE ISOLATION BARRIERS AND METHODS FOR FORMING AND USING SUCH BARRIERS Ultradent Products, Inc. (US) 2000-04-12 EP claimed
US-6048202-A THE POLYMERIZABLE ISOLATION BARRIER COMPRISING THE MIXTURE PRODUCTS OF ATLEAST ONE MONOMER, A CURING AGENT FOR CURING THE MONOMER AND A TISSUE ADHERENCE ACCENTUATOR SUCH AS GUM OR CELLULOSE PRODUCT ULTRADENT PRODUCTS, INC. (US) 2000-04-11 US claimed
WO-1998036700-A1 POLYMERIZABLE ISOLATION BARRIERS AND METHODS FOR FORMING AND USING SUCH BARRIERS ULTRADENT PRODUCTS, INC. (US) 1998-08-27 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11666514-B2 Fibrous structures containing polymer matrix particles with perfume ingredients FSCN1, FLNA, PFN1 ALOX15 962/4885HSD17B10 2505/4885KDM4E 4788/4885
US-20200093710-A1 FIBROUS STRUCTURES CONTAINING POLYMER MATRIX PARTICLES WITH PERFUME INGREDIENTS FSCN1, FLNA, PFN1 ALOX15 962/4885HSD17B10 2505/4885KDM4E 4788/4885
US-20230060806-A1 DISSOLVABLE SOLID STRUCTURE COMPRISING FIRST AND SECOND POLYMERIC STRUCTURANTS SGMS2, DEGS1, SGMS1 ALOX15 1418/4885HSD17B10 1794/4885KDM4E 4780/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.